Which medication classes have been shown to decrease mortality in patients with symptomatic heart failure?

Which medication classes have been shown to decrease mortality in patients with symptomatic heart failure?

• A. Angiotensin receptor blockers only
• B. Calcium channel blockers
• C. Diuretics alone
• D. Aldosterone antagonists, beta-blockers

Answer: (D)

In heart failure with reduced ejection fraction, mortality is reduced by drugs that counteract the harmful effects of chronic neurohormonal activation and cardiac remodeling. Beta-blockers do this by blunting sympathetic overstimulation, lowering heart rate, improving ventricular filling, and reducing arrhythmias. Large trials have shown they cut all-cause mortality and sudden death in symptomatic HF, improving outcomes when started and titrated carefully after stabilization. Aldosterone antagonists add a complementary effect by blocking mineralocorticoid receptors. Aldosterone promotes myocardial and vascular fibrosis, sodium and water retention, and adverse remodeling; blocking its action with agents like spironolactone or eplerenone reduces these processes and has been demonstrated to decrease mortality in major studies such as RALES and EPHESUS. Calcium channel blockers and diuretics alone do not reduce mortality in this setting. Calcium-channel blockers have not shown a mortality benefit in systolic HF and can be neutral or harmful in some patients, while diuretics relieve congestion and symptoms but do not improve survival. Thus, the classes with proven mortality benefit in symptomatic heart failure are aldosterone antagonists and beta-blockers, and they are cornerstone components of evidence-based HF management.

In heart failure with reduced ejection fraction, mortality is reduced by drugs that counteract the harmful effects of chronic neurohormonal activation and cardiac remodeling. Beta-blockers do this by blunting sympathetic overstimulation, lowering heart rate, improving ventricular filling, and reducing arrhythmias. Large trials have shown they cut all-cause mortality and sudden death in symptomatic HF, improving outcomes when started and titrated carefully after stabilization.

Aldosterone antagonists add a complementary effect by blocking mineralocorticoid receptors. Aldosterone promotes myocardial and vascular fibrosis, sodium and water retention, and adverse remodeling; blocking its action with agents like spironolactone or eplerenone reduces these processes and has been demonstrated to decrease mortality in major studies such as RALES and EPHESUS.

Calcium channel blockers and diuretics alone do not reduce mortality in this setting. Calcium-channel blockers have not shown a mortality benefit in systolic HF and can be neutral or harmful in some patients, while diuretics relieve congestion and symptoms but do not improve survival.

Thus, the classes with proven mortality benefit in symptomatic heart failure are aldosterone antagonists and beta-blockers, and they are cornerstone components of evidence-based HF management.